尿激酶原的性质、结构、功能及其药代动力学和临床应用效果

溶栓疗法不仅已被常规地用于急性心肌梗死的治疗,而且也已用于其它血栓病的治疗中,如急性缺血性脑血栓、肺栓塞、急性周围动脉血栓等。尿激酶原是双链尿激酶的单链前体,它主要激活纤维蛋白表面的纤溶蛋白原,所以具有选择性溶栓作用。临床结果表明它是一种安全有效的溶栓药物,与t-PA、链激酶或尿激酶伍用均有协同作用。本文综述它了的特性、结构与功能,以及它的药代动力学和临床的治疗效果。

The characteristics, structure and functions, pharmacokinetics and clinical results of prourokinase

Thrombolytic therapy has not only been used as a routine approach in treatment of acute my-ocardial infarction, but also been used in other thromboembolic diseases, such as acute ischaemic stroke, pulmonary embolism, acute peripheral arterial thrombosis and so on. Prourokinase is the single-chain precursor of two-chain urokinase. It activates plasminogen preferentially at the fibrin surface and induces fibrin-selective clot lysis. Clinical results have shown that prourokinase is a safe and efficient thrombolytic agent, and can exhibite synergistic effects when it is used combined with t-PA, streptokinase or urokinase. This article will review its characteristics, structure and functions, pharma-cokinetics and its clinical results.